Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 56, Issue 8, 2007, Pages 2679-2686

  Kinder, Brent W ^a   Freemer, Michelle M ^a   King Jr , Talmadge E ^a   Lum, Raymond F ^a   Nititham, Joanne ^a   Taylor, Kim ^a   Edberg, Jeffrey C ^b   Bridges Jr , S Louis ^b   Criswell, Lindsey A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FC GAMMA RECEPTOR IIA; FC RECEPTOR; HYDROXYCHLOROQUINE; IMMUNOMODULATING AGENT; MANNOSE BINDING LECTIN; METHOTREXATE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; COHORT ANALYSIS; ETHNIC GROUP; FCGR2A GENE; FEMALE; GENDER; GENE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HIGH RISK PATIENT; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MBL GENE; MORBIDITY; MULTIVARIATE ANALYSIS; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TNF GENE; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CALIFORNIA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COMORBIDITY; ETHNIC GROUPS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MANNOSE-BINDING LECTIN; MIDDLE AGED; ODDS RATIO; PNEUMONIA; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IGG; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34547765291     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22804     Document Type: Article

References (40)

1. Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, et al. Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun 2004;5:641-7.
2. Domingo P, Muniz-Diaz E, Baraldes MA, Arilla M, Barquet N, Pericas R, et al. Associations between Fcγ receptor IIA polymorphisms and the risk and prognosis of meningococcal disease. Am J Med 2002;112:19-25.
3. Sanders EA, Van de Winkel JG, Feldman RG, Voorhorst-Ogink MM, Rijkers GT, Capel PJ, et al. Fcγ IIA receptor phenotype and opsonophagocytosis in two patients with recurrent bacterial infections. Immunodeficiency 1993;4:163-5.
4. Yee AM, Ng SC, Sobel RE, Salmon JE. FcγRIIA polymorphism as a risk factor for invasive pneumococcal infections in systemic lupus erythematosus. Arthritis Rheum 1997;40:1180-2.
5. Lee YH, Harley JB, Nath SK. Meta-analysis of TNF-α promoter -308 A/G polymorphism and SLE susceptibility. Eur J Hum Genet 2006;14:364-71.
6. Lee YH, Witte T, Momot T, Schmidt RE, Kaufman KM, Harley JB, et al. The mannose-binding lectin gene polymorphisms and systemic lupus erythematosus: two case-control studies and a meta-analysis. Arthritis Rheum 2005;52:3966-74.
7. Seligman VA, Suarez C, Lum R, Inda SE, Lin D, Li H, et al. The Fcγ receptor IIIA-158F allele is a major risk factor for the development of lupus nephritis among Caucasians but not non-Caucasians. Arthritis Rheum 2001;44:618-25.
8. Noel V, Lortholary O, Casassus P, Cohen P, Genereau T, Andre MH, et al. Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis 2001;60:1141-4.
9. Gladman DD, Hussain F, Ibanez D, Urowitz MB. The nature and outcome of infection in systemic lupus erythematosus. Lupus 2002;11:234-9.
10. Edwards CJ, Lian TY, Badsha H, Teh CL, Arden N, Chng HH. Hospitalization of individuals with systemic lupus erythematosus: characteristics and predictors of outcome. Lupus 2003;12:672-6.
11. Staples PJ, Gerding DN, Decker JL, Gordon RS Jr. Incidence of infection in systemic lupus erythematosus. Arthritis Rheum 1974;17:1-10.
12. Petri M, Genovese M. Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: a prospective study of the Hopkins Lupus Cohort. J Rheumatol 1992;19:1559-65.
13. Duffy KN, Duffy CM, Gladman DD. Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients. J Rheumatol 1991;18:1180-4.
14. Netea MG, Radstake T, Joosten LA, van der Meer JW, Barrera P, Kullberg BJ. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-γ production and Toll-like receptor 4 expression. Arthritis Rheum 2003;48:1853-7.
15. Sipahi T, Pocan H, Akar N. Effect of various genetic polymorphisms on the incidence and outcome of severe sepsis. Clin Appl Thromb Hemost 2006;12-54.
16. Gordon AC, Lagan AL, Aganna E, Cheung L, Peters CJ, McDermott MF, et al. TNF and TNFR polymorphisms in severe sepsis and septic shock: a prospective multicentre study. Genes Immun 2004;5:631-40.
17. Yuan FF, Wong M, Pererva N, Keating J, Davis AR, Bryant JA, et al. FcγRIIA polymorphisms in Streptococcus pneumoniae infection. Immunol Cell Biol 2003;81:192-5.
18. Moens L, Van Hoeyveld E, Verhaegen J, De Boeck K, Peetermans WE, Bossuyt X. Fcγ-receptor IIA genotype and invasive pneumococcal infection. Clin Immunol 2006;118:20-3.
19. Koch A, Melbye M, Sorensen P, Homoe P, Madsen HO, Molbak K, et al. Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. JAMA 2001;285:1316-21.
20. Summerfield JA, Sumiya M, Levin M, Turner MW. Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. BMJ 1997;314:1229-32.
21. Summerfield JA, Ryder S, Sumiya M, Thursz M, Gorchein A, Monteil MA, et al. Mannose binding protein gene mutations associated with unusual and severe infections in adults. Lancet 1995;345:886-9.
22. Garred P, Madsen HO, Halberg P, Petersen J, Kronborg G, Svejgaard A, et al. Mannose-binding lectin polymorphisms and susceptibility to infection in systemic lupus erythematosus. Arthritis Rheum 1999;42:2145-52.
23. Garred P, Voss A, Madsen HO, Junker P. Association of mannose-binding lectin gene variation with disease severity and infections in a population-based cohort of systemic lupus erythematosus patients. Genes Immun 2001;2:442-50.
24. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
25. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
26. Souweine B, Veber B, Bedos JP, Gachot B, Dombret MC, Regnier B, et al. Diagnostic accuracy of protected specimen brush and bronchoalveolar lavage in nosocomial pneumonia: impact of previous antimicrobial treatments. Crit Care Med 1998;26:236-44.
27. Timsit JF, Misset B, Francoual S, Goldstein FW, Vaury P, Carlet J. Is protected specimen brush a reproducible method to diagnose ICU-acquired pneumonia? Chest 1993;104:104-8.
28. Marquette CH, Georges H, Wallet F, Ramon P, Saulnier F, Neviere R, et al. Diagnostic efficiency of endotracheal aspirates with quantitative bacterial cultures in intubated patients with suspected pneumonia: comparison with the protected specimen brush. Am Rev Respir Dis 1993;148:138-44.
29. Fagon JY, Chastre J, Hance AJ, Domart Y, Trouillet JL, Gibert C. Evaluation of clinical judgment in the identification and treatment of nosocomial pneumonia in ventilated patients. Chest 1993;103:547-53.
30. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can Respir J 2000;7:371-82.
31. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50.
32. Edberg JC, Langefeld CD, Wu J, Moser KL, Kaufman KM, Kelly J, et al. Genetic linkage and association of Fcγ receptor IIIA (CD16A) on chromosome 1q23 with human systemic lupus erythematosus. Arthritis Rheum 2002;46:2132-40.
33. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
34. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001;345:1098-104.
35. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001;344:1099-100.
36. Knight JC, Keating BJ, Kwiatkowski DP. Allele-specific repression of lymphotoxin-α by activated B cell factor-1. Nat Genet 2004;36:394-9.
37. Kaijzel EL, van Krugten MV, Brinkman BM, Huizinga TW, van der Straaten T, Hazes JM, et al. Functional analysis of a human tumor necrosis factor α (TNF-α) promoter polymorphism related to joint damage in rheumatoid arthritis. Mol Med 1998;4:724-33.
38. Elkayam O, Paran D, Caspi D, Litinsky I, Yaron M, Charboneau D, et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 2002;34:147-53.
39. Update on adult immunization: recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991;40:1-94.
40. Lockhart PB, Brennan MT, Fox PC, Norton HJ, Jernigan DB, Strausbaugh LJ. Decision-making on the use of antimicrobial prophylaxis for dental procedures: a survey of infectious disease consultants and review. Clin Infect Dis 2002;34:1621-6.